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ABSTRACT
It is known that siRNAs are capable of reducing
expression of non-target genes due to the interac-
tion of the siRNA guide strand with a partially com-
plementary site on the ‘off-target’ mRNA. In the
current study, we show that reduction of cellular
Ago2 levels has no effect on off-target reduction of
endogenous genes and that off-target degradation
of mRNA can occur even in an Ago2 knockout
cell line. Using antisense mediated reduction of
Ago proteins and chemically modified cleavage-
and binding-deficient siRNAs, we demonstrate that
siRNA mediated off-target reduction is Ago2
cleavage independent, but does require siRNA inter-
action with either Ago1 or Ago2 and the RISC-
loading complex. We also show that depletion of
P-body associated proteins results in a reduction
of off-target siRNA-mediated degradation of
mRNA. Finally, we present data suggesting that a
significant portion of on-target siRNA activity is
also Ago2 cleavage independent, however, this
activity does not appear to be P-body associated.
INTRODUCTION
RNA interference (RNAi) is a mechanism by which
double-stranded RNA triggers the inhibition of target
gene expression by inducing sequence-speciﬁc target
mRNA degradation (1). Short interfering RNAs
(siRNAs), exogenously administered RNA duplexes of
21–23 nucleotides, lead to degradation of speciﬁc
mRNAs through the RNA-induced silencing complex
(RISC) (2). After cellular delivery of synthetic siRNAs,
the double stranded molecules are incorporated into the
RISC-loading complex (RLC), which consists of Ago2,
Dicer and the HIV trans-activating response RNA-
binding protein (TRBP) (3). Prior to target mRNA
recognition, an siRNA duplex goes through an ATP-
dependent unwinding process and one of the two siRNA
strands, referred to as the passenger strand, is released,
while the other strand (guide strand) remains bound to
the Argonaut protein, Ago2 (4,5). This strand then
facilitates interaction of RISC with its complementary
target RNA, which is ﬁnally cleaved at the site opposite
the 10th and 11th positions of the siRNA guide strand by
the RNase activity located in the Ago2 protein, triggering
its destruction (6–11).
It has been reported that siRNAs can eﬀectively reduce
expression of mRNAs even when there are a few
mismatches between the siRNA and the mRNA target
sequence (12,13). Microarray analyses have shown that
siRNAs with partial complementarity to an mRNA can
cause a reduction in the levels of non-targeted messages
(14–16). Additional studies demonstrated that six to seven
consecutive matches between the 50-end of siRNA guide
strand and the ‘oﬀ-target’ RNA as well as the context of
the matching sequence within the oﬀ-target RNA are
important parameters that determine if an oﬀ-target
mRNA is degraded (17,18).
Like siRNA mediated oﬀ-target RNA degradation, it
has been reported that miRNAs, naturally produced small
RNAs that work through RISC, can reduce the levels of
partially complementary target genes (19–21). Consistent
with the oﬀ-target activity observed with siRNAs,
miRNA-mediated RNA degradation requires a homolo-
gous ‘seed region’ 2–7 nucleotides from the 50-end of the
miRNA (22–24). In addition, it has been reported that
Drosophila embryos lacking Ago2, which are not capable
of siRNA-directed cleavage, are still capable of miRNA-
directed target RNA reduction (8) through deadenylation
and subsequent degradation of target transcripts in a
process which likely involves P-bodies (25–27). Recent
studies employing reporter genes suggest that siRNA-
mediated oﬀ-target mRNA reduction is also the result
of Ago2-independent degradation processes (28,29);
however, the mechanism of oﬀ-target mRNA degradation
has not been fully elucidated.
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miRNA-mediated mRNA reduction suggest that they
may share common mechanisms. However, since almost
all siRNAs contain chemical modiﬁcations (30,31) it
cannot simply be assumed that they have the same
properties as endogenously produced miRNAs. In
addition, the transfection process required for siRNA
activity may also inﬂuence sub-cellular localization and
activity of siRNA relative to miRNA (32). In the
current study, we present data from experiments utilizing
Ago2-reduced and Ago2 knockout cell lines, which
conﬁrm that siRNA mediated oﬀ-target degradation of
endogenous mRNAs can occur independently of Ago2.
In addition, our data also suggest that interaction of the
siRNA with the RLC is required for oﬀ-target activity, as
Dicer cleavage of long dsRNAs is required for activity.
We also demonstrate that Ago binding, but not cleavage
is necessary for siRNA-mediated oﬀ-target degradation of
RNA and show that Ago1 is capable of mediating oﬀ-
target mRNA downregulation. Reductions in the levels
of siRNA and miRNA related proteins suggest that
siRNA oﬀ-target degradation and miRNA-mediated
target degradation share common pathways; namely
degradation of the mRNA is associated with cellular
P-bodies. Finally, our data strongly suggest that at least
some siRNA on-target activity is also Ago2 independent,
however, this activity appears to occur independently of
the P-body proteins that we have evaluated.
MATERIALS AND METHODS
Preparation of antisense oligonucleotides and siRNAs
Synthesis and puriﬁcation of phosphorothioate/20-MOE
oligonucleotides was performed using an Applied
Biosystems 380B automated DNA synthesizer as
described previously (33). All RNaseH-dependent ASOs
used for target mRNA reduction were 18–20 bases in
length, full phosphorothioate with 20-O-methoxyethyl
(20MOE) substitutions at the positions indicated by bold
type. The sequences of the ASOs are as follows: PIK3CB
(NM_006219, RefSeq ID: PIK3CB): TAGGATTCATAT
TAGGAG (ISIS 405249); Ago2 (NM_012154, RefSeq
ID: EIF2C2): CTGCTGGAATGTTTCCACTT (ISIS
136764); Dicer (NM_030621, RefSeq ID: DICER1): GC
TGACCTTTTTGCTTCTCA (ISIS 138648); FEN1
(NM_004111.4, RefSeq ID:FEN1): TGGCTGGTGGTC
TCACCCTC (ISIS 366372); mouse Ago1 (NM_153403,
RefSeq ID: Eif2c1): CTGGACTATTTGCATAGCAA
(ISIS 395392); mouse Ago2 (NM_153178, RefSeq
ID: EIF2C2): CGTCTCATGTTCGATGCTGG (ISIS
395507); mouse DDX6 (NM_007841, RefSeq ID: Ddx6):
CTCGGGTAAACAGATCAGTG (ISIS 339800); mouse
DCP1A (NM_133761, RefSeq ID: Dcp1a): CACCATGT
TGCTCAGGGAGG (ISIS 368473); mouse DCP2
(NM_027490, RefSeq ID: Dcp2): CTGCATGTAGAAA
TCCAAGT (ISIS 365128); mouse GW182 (NM_144925,
RefSeq ID: Tnrc6a): TCCTCAGTAGATTTCCATCC
(ISIS 443335). Silencer Pre-designed siRNAs for knock-
down of RISC and P-Body proteins were obtained from
Ambion (Austin, TX). Ago2: siRNA ID# 133832;
GW182: siRNA ID# 135276; Lsm-1 siRNA ID# s84653.
PIK3CB (15), YY1 and mPIK3CB synthetic unmodiﬁed
siRNAs were purchased from Dharmacon Research, Inc
(Boulder, CO). Sequences of the siRNA sense strands are
as follows:
PIK3CB: 50-UCUCCUAAUAUGAAUCCUAU-30
YY1: 50-AUUUUAAAAAUGAAUCCUAC-30
mPIK3CB: 50-CUCCCAAUUUGAAUCCUAU-30
MOE modiﬁed PIK3CB siRNAs were synthesized
as previously described (34). The positions of the
MOE substituted nucleotides on the antisense strand
are underlined: AUAGGAUUCAUAUUAGGAGU
(siPIK3CB 12–14) and AUAGGAUUCAUAUUAGGA
GU (siPIK3CB 1–3). The siRNA sense strand is
unmodiﬁed RNA. The sequence of the PIK3CB 40-mer
‘dicer-substrate’ siRNA is CUCCUAAUAUGAAUCCU
AUCAAAGUAAAUGAAUUGGCAAU (sense) and A
UUGCCAAUUCAUUUACUUUGAUAGGAUUCAUA
UUAGGAGAC (antisense). The sequence of the 19-mer is
highlighted within the 40-mer. A two base overhang was
added to the antisense strand to ensure directionality of
Dicer cleavage.
siRNA/ASO treatment
Tissue culture medium, trypsin, Lipofectamine
RNAiMAX and Lipofectamine 2000 were purchased
from Invitrogen (Carlsbad, CA). HeLa cells were
obtained from the American Type Tissue Collection
(Manassas, VA). Wild-type and Ago2 knockout mouse
embryonic ﬁbroblasts (MEF) were a kind gift of Dr
Gregory J. Hannon. Cells were cultured in DMEM sup-
plemented with 10% fetal calf serum, streptomycin
(0.1mg/ml), and penicillin (100U/ml). For the knockdown
of RISC or P-Body associated genes, cells were treated at
30–100nM with the indicated ASO/siRNA in Opti-MEM
media (Invitrogen) containing 4mg/ml Lipofectamine 2000
for ASOs or 6mg/ml Lipofectamine RNAiMAX for 4h at
37 C, as described previously (35). Cells were split 24–72h
after the start of ASO treatment and seeded in 96
-ell plates at 4500 cells/well. Cells were allowed to
adhere to the plates for 4h then treated with the siRNA
or ASO targeting PIK3CB. For the generation of
IC50 curves, cells treated as above at concentrations
ranging from 0.1 to 300nM in half-log serial dilutions
(N=3–4/dose). The next day, total RNA was puriﬁed
from 96-well plates using an RNeasy 3000 BioRobot
(Qiagen, Valencia, CA) and PIK3CB mRNA levels
assessed by quantitative reverse transcriptase polymerase
chain reaction (qRT–PCR).
Reduction of target mRNA expression was determined
by qRT–PCR performed essentially as described elsewhere
(36). Brieﬂy, 200ng of total RNA was analyzed in a ﬁnal
volume of 50ml containing 200nM gene-speciﬁc PCR
primers, 0.2mM of each dNTP, 75nM ﬂuorescently
labeled oligonucleotide probe, 5ml RT–PCR buﬀer,
5mM MgCl2, 2U of Platinum Taq DNA Polymerase
(Invitrogen) and 8U of RNase inhibitor. Reverse tran-
scription was performed for 30min at 48 C followed by
PCR: 40 thermal cycles of 30s at 94 C and 1min at 60 C
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Biosystems). To avoid artifacts based upon well-to-well
variation in cell number, mRNA levels were normalized
to the total amount of RNA present in each reaction as
determined by Ribogreen assay (37) (Invitrogen). IC50
curves and P-values were generated using Prism 4
software (GraphPad). Sigmoidal dose response was
calculated according to Y=Bottom+(Top–Bottom)/
{1+10[(logEC50 X)]}; where X is the logarithm of con-
centration and Y is the response. The sequence for
the human PIK3CB primer/probe set used in the RT–
PCR reaction is GGGAAGGAGGCCATGCAT for the
forward primer, CAACATAGAGTTCTGAGAGGATA
ACACA for the reverse primer and TGACCTGCAGTC
ACCCCTGAACCC for the probe. The sequence for the
human YY1 primer/probe set GCGAATCCATACCGG
AGACA for the forward primer, AGGTTAGTTGACTG
AGCAAACTTCTTATT for the reverse primer and CCC
TATGTGTGCCCCTTCGATGGTT for the probe. The
sequence for the human FADD primer/probe set GTCAT
GGAACTCAGACGCATCT for the forward primer, TC
CACCAGCGCAAAGCA for the reverse primer and CC
TCCGAAGCGTCCTGATGGGC for the probe. The
sequence for the mouse YY1 primer/probe set is ACAA
CCAGTGAAAAGAAGAGAGAAGAC for the forward
primer, AGAGGCATATTTATTCCCAATCACA for
the reverse primer and TTCTCGACCCGGGAAGCCT
CTTCA for the probe.
Primer probe sets used to analyze the levels of targeted
RISC/P-body genes are as follows. Human Ago2: CCAG
CTACACTCAGACCAACAGA (forward primer), GAA
AACGGAGAATCTAATAAAATCAATGAC (reverse
primer) and CGTGACAGCCAGCATCGAACATGAG
A (probe). Human Ago1: GAGCCTATGTTCCGGCAT
CTC (forward primer), AGAGTGTATCTCCGACACG
TTTCAC (reverse primer) and AGCATACACCGGCGT
CTTCCCTGG (probe). Human Dicer: ATTAACCTTTT
GGTGTTTGATGAGTGT (forward primer), GCGAGG
ACATGATGGACAAATT (reverse primer) and ATCTT
GCAATCCTAGACCACCCCTATCGAGAA (probe).
Human Lsm1: TGTGCATTGCAGCATTATTTCA
(forward primer), CTTTTTGTCAATGTCCTCGATGA
G (reverse primer) and CAAAATGAACTATATGCCT
GGCACCGCC (probe). Human GW182: CAAACAAC
GGTGGCCTGAAT (forward primer), AATCGCTGTA
ACTGGGAGATCTG (reverse primer) and CCTCAACA
GGTAGCCATGCTGAACCAG (probe). Mouse Ago1:
AGTGATGCCAACACTCCATCTG (forward primer),
AGGGTGATGGAACACGAAGTAGA (reverse primer)
and CCTGTCCATCGCCTTCATAGACA (probe).
Mouse Ago2: CCATCTAGCTGTGAAGGCTCTGA
(forward primer), TTCTTAGGGCCAGGCTTTAAAA
(reverse primer) and CATGAAAGCCACACCATTTCC
ATTGGG (probe). Mouse DDX6: GCAAAAGCGGTG
CCTACCT (forward primer), CACCATTGCTTGAATA
TTGTCCTT (reverse primer) and TCCCCTTACTTGAA
AGGCTGGACCTGA (probe). Mouse GW182: GACAA
TGTCATGCCCCACACT (forward primer), CAAGCCT
ATAGGAAAGTTGCTGAAA (reverse primer) and CA
CCCGAGCTGCAGAAAGGGCC (probe).
Recombinant human Ago2 activity assay
Cloning and puriﬁcation of human recombinant Ago2 is
detailed in Supplementary Data. For human GST-Ago2
cleavage activity, 1ng recombinant Ago2 was incubated at
37 C with 10nM of either PIK3CB siRNA guide strand in
cleavage buﬀer (10mM Tris, pH 7.5, 100mM KCl, 2mM
MgCl2, Protease Inhibitor and 0.5mM DTT). After 2h,
0.1nM
32P labeled 40-mer target RNA was added. The
sequence of the PIK3CB target was CUUUCAAGU
GUCUCCUAAUAUGAAUCCUAUCAAAGUAAAU
(siRNA compliment in bold) and the sequence of the YY1
target was UCUAGGAAGAAUUUUAAAAAUGAAUC
CUACACACCUAAGG (seed region underlined). After
30min cleavage reactions were quenched in gel loading
buﬀer (Ambion, TX). Cleavage products were resolved
by denaturing PAGE and quantitated with Storm 850
Phosphorimager (Molecular Dynamics).
Human Ago2-binding assay
The binding aﬃnity of siRNA antisense strands to human
GST-Ago2 was determined by homologous saturation
using recombinant Ago2.
32P-labeled oligoribonucleotide
was incubated with 1ng GST-Ago2 enzyme in the
presence of increasing concentrations of unlabeled
PIK3CB, PIK3CB-M1-3 or PIK3CB-M12-14 siRNA
guide strand ranging in concentration from 100pM to
10mM. The enzyme was added to 50ml of Miltenyi
Biotec mMACS Anti-GST Microbeads (Auburn, CA)
and allowed to bind for 2h. The beads were then loaded
onto paramagnetic columns supplied by Miltenyi and
unbound
32P-labeled oligoribonucleotide was washed
away with 1ml of cleavage buﬀer. The remaining, i.e.
bound, radio-activity was counted in a scintillation
counter and the bound counts were plotted as a function
of the concentration of the unlabeled oligoribonucleotide.
The dissociation constants (Kd) were calculated from non-
linear least-squares ﬁt of the data to the equation for the
one-site binding hyperbola (Y=Bmax* X/Kd+X; where
Bmax is maximum binding and Kd is the concentration of
unlabeled oligoribonucleotide at half-maximal binding).
The errors reported for the binding aﬃnities are based
on three trials.
RLM-RACE mapping of Ago2 cleavage sites
HeLa cells were transfected with 100nM PIK3CB or
YY1 siRNA in Opti-MEM media containing 6mg/ml
Lipofectamine RNAiMAX for 16h at 37 C, as described
above. Total RNA was harvested 16h after transfection
using an RNAeasy kit (Qiagen). One microgram of total
RNA was ligated to FirstChoice 50 RACE Adapter RNA
oligo (Applied Biosystems, Foster City, CA). The ligated
products were reverse transcribed using random decamers
and MMLV-RT according to the manufacturer’s guide-
lines. The resulting cDNAs were ampliﬁed by successive
rounds of PCR with nested pairs of primers. The ﬁrst
round of PCR was performed for 30 cycles using the 50
RACE adaptor outer FP and either the PIK3CB outer RP
50-CCAGCCCTGACATGAACTTT-30 or YY1 outer RP
50-CAACCAAAATTAAGATAGCAAACAAA-30. The
Nucleic Acids Research, 2009,Vol.37, No. 20 6929second round of PCR was performed for 40 cycles using
the 50 RACE adaptor inner FP and either the PIK3CB
inner RP 50-TTTGGTGGTAATGGAAGAGGA-30 or
YY1 inner RP 50-AACCTCCAGAAAAATCACACG-30.
RT–PCR production were run on a 2% agaraose gel in 1 
TBE buﬀer and visualized by ethidium bromide staining.
PCR products were excised from the gel, puriﬁed, then
cloned into the pCR2.1-TOPO vector (Invitrogen)
according to the manufacturer’s protocol. Clones were
sequenced to conﬁrm putative siRNA cleavage sites.
Gene expression array analysis
Wild-type and Ago2
 /  knockout MEF cells in 6-well
plates were treated PIK3CB siRNA at a concentration
of 10nM using ml Lipofectamine RNAiMAX as detailed
above. The following day total RNA was puriﬁed from
mock-transfected and siRNA treated cells using RNeasy
mini columns according to the manufacturer’s protocol
(Qiagen). Microarray analysis using Aﬀymetrix Mouse
Genome 430 2.0 arrays was performed by Expression
Analysis (Durham, NC). Microarray data were analyzed
using Array Studio (Omicsoft, Durham, NC). Log2
expression ratios were derived by subtracting log2 hybrid-
ization intensities to each probe in samples from mock-
transfected cells from log2 hybridization intensities in
samples from transfected cells. Log2 expression ratios
were sorted and sets of associated 30UTR regions were
analyzed for over or under-represented hexamer word
strings using Sylamer (38) (http://www.sanger.ac.uk/
Teams/Team101/sylamer/). Log2 expression ratios were
sorted by degree of down-regulation and binned into
sets of 400–500 probes. The frequency of transcripts con-
taining each hexamer motif in 30UTRs from each bin was
compared with the frequency of that motif in the back-
ground set of 30UTRs representing the entire microarray.
The signiﬁcance of enrichment of each hexamer motif was
calculated using a hypergeometric P-value.
RESULTS
Ago2 is not required for PIK3CB oﬀ-target and some
on-target siRNA activity
It has recently been demonstrated that siRNA-dependent
oﬀ-target mRNA reduction of stably and transiently
expressed reporter genes is attributable to Ago2-
independent degradation processes (28,29). To better
understand the role of Ago2 in siRNA-mediated oﬀ-
target degradation of endogenous mRNAs, we used a
previously described siRNA targeting human PIK3CB
which was demonstrated to reduce mRNA for two non-
targeted transcripts, FADD and YY1, putatively via
sequence complementarity to the seed region of the
PIK3CB siRNA (15). PIK3CB siRNA or an RNaseH-
dependent chimeric phosphorothioate/20-MOE antisense
oligonucleotide (ASO) of the same sequence (ISIS
405249) were administered to control HeLa cells and
cells that had been treated for 24h with ASOs targeting
either Ago2 or FEN-1. Depletion of Ago2 resulted in an
 6-fold reduction in the potency of the siRNA for
PIK3CB and had no eﬀect on the potency of the
RNaseH ASO (Figure 1A and B, blue lines). As
expected reduction of the nuclease FEN-1, had no eﬀect
on the target-speciﬁc activity of either the siRNA or ASO
(red lines). Although reduction of Ago2 was  80% under
our transfection conditions (Supplementary Figure S1),
siRNA target-speciﬁc reduction of PIK3CB was still
quite potent (IC50: 60nM), suggesting that even for
siRNA on-target eﬀects, the ‘slicer’ activity of Ago2 may
not be the only mechanism involved in reducing levels of
the targeted RNA. Oﬀ-target reduction of FADD and
YY1 mRNA were also evaluated. While neither FADD
(black lines) nor YY1 (red lines) mRNA was reduced by
the RNaseH ASO (Figure 1D), both FADD and YY1
were reduced in a concentration-dependent manner by
PIK3CB siRNA (Figure 1C). In contrast to the
on-target reduction of PIK3CB mRNA, no change in
potency was observed with Ago2 reduction for the oﬀ-
target transcripts (dotted lines).
On- and Oﬀ-target activities require ‘dicing’ of a
40-mer RNA duplex
Since our results indicated that siRNA oﬀ-target activity
may occur independently of Ago2, we wondered whether
oﬀ-target activity may also occur independently of other
RISC associated proteins. It has previously been shown
that RNA duplexes 27 base pairs and greater in length
require the presence of Dicer for cleavage into 21–22
base duplexes capable of activating RISC (39). To inves-
tigate the eﬀect of Dicer reduction on both on- and
oﬀ-target activity, the potency of the 19-mer PIK3CB
siRNA was compared with a 40-mer RNA duplex target-
ing the same site. HeLa cells were ﬁrst treated with 50nM
ASO targeting either Ago2 or Dicer. Twenty-four hours
later, the cells were seeded in 96-well plates then
transfected with 19- or 40-mer PIK3CB siRNAs. On-
and oﬀ-target IC50 values for the PIK3CB siRNA
and Dicer substrate were assessed the following day. The
reductions of Ago2 and Dicer were also evaluated
by qRT–PCR and found to be >80% for both mRNAs.
As previously observed, Ago2 reduction (Figure 2A,
blue lines) resulted in decreased on-target potency of
the 19-mer siRNA, however, reduction of Dicer (red
lines) had no eﬀect. Oﬀ-target potency of the 19-mer
siRNA, as measured by reduction of the YY1 transcript,
was not aﬀected by either Dicer or Ago2 reduction
(Figure 2B). For the 40-mer siRNA, both Ago2 and
Dicer appear to be required for on-target activity, as
reduction of either RISC component resulted in a
similar attenuation of activity (Figure 2C). In contrast,
oﬀ-target siRNA activity of the 40-mer was diminished
only by Dicer reduction (Figure 2D), while reduction
of Ago2 had no eﬀect on potency. Again, these data
suggest that oﬀ-target, as well as a portion of on-target
activity; of either a 19- or 40-mer siRNA may occur
independently of Ago2 cleavage. However, the require-
ment of ‘dicing’ of the 40-mer siRNA suggests that
RISC loading is necessary for both on- and oﬀ-target
activities.
6930 Nucleic Acids Research, 2009,Vol.37, No. 20RACE product is detected only for target-speciﬁc,
Ago2-dependent cleavage
We used a modiﬁed RLM-RACE protocol to further
conﬁrm that oﬀ-target mRNA degradation is not
associated with cognate Ago2 cleavage. HeLa cells were
transfected with 30nM of either PIK3CB siRNA or a
siRNA designed with perfect complementarity to the
YY1 oﬀ-target site. Eighteen hours later total RNA was
isolated. Analysis of on- and oﬀ-target mRNA reduction
by qRT–PCR conﬁrmed that both PIK3CB and YY1
were reduced by treatment with the PIK3CB siRNA,
while only YY1 was reduced by the YY1 speciﬁc siRNA
(Figure 3A). Mapping of degradation products was per-
formed using rapid ampliﬁcation of cDNA ends (50
RACE) on the mRNA (28). Canonical siRNA-mediated
cleavage by Ago2 at position 10 results in a 30-cleavage
product that leaves a 50 phosphate which is ligation com-
petent and can therefore act as a substrate for 50 RACE.
The RACE adapter ligated products were reverse
transcribed, then ampliﬁed using nested PCR using
primers complementary to the RACE RNA adapter
sequence and the PIK3CB or YY1 sequences 30 of the
purported Ago2 cleavage site. A PCR product of
 288bp, consistent with the size of the expected ampliﬁed
PIK3CB cleavage product and the location of the primers
used during nested PCR, was observed with RNA
from cells transfected with the PIK3CB siRNA (Figure
3B, lane 2). Sequencing of the cloned PCR product estab-
lished cleavage at the expected base, conﬁrming that at
least some of the initial cleavage of the targeted mRNA
by the siRNA was a direct consequence of Ago2/RISC
activity. Likewise, PCR ampliﬁcation with YY1 speciﬁc
primers resulted in a detectable PCR product of the
expected size of  339bp for cells treated YY1 siRNA
(lane 6). The expected YY1 cleavage site was also con-
ﬁrmed by sequencing of the PCR product. However,
despite approximately equal reduction of the YY1
mRNA with the PIK3CB siRNA than with the YY1
siRNA, no cleavage product was observed for the
YY1 oﬀ-target mRNA (lane 5), again suggesting that
oﬀ-target degradation of an endogenous gene can occur
independently of Ago2 cleavage, and that these observa-
tions cannot be explained by the inability to amplify low
abundance degradation products.
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Figure 1. Ago2 reduction attenuates target-speciﬁc, but not oﬀ-target PIK3CB activity. ASO-mediated reduction of Ago2 or FEN1 was performed
for 24 h prior to PIK3CB siRNA/ASO treatment. Cells were then split and seeded in 96-well plates. Cells were allowed to adhere to the plates for 4h
then treated with siRNA targeting PIK3CB or an RNAseH-dependent chimeric phosphorothioate/20-MOE oligonucleotide of the same sequence
(ISIS 405249). Cells were harvested the following day, total RNA puriﬁed and PIK3CB mRNA levels assessed by qRT–PCR (A) Percent reduction
of PIK3CB mRNA by PIK3CB siRNA in control (black), Ago2-reduced (blue) and FEN1-reduced (red) HeLa cells. (B) Percent reduction
of PIK3CB mRNA by PIK3CB RNAseH ASO. (C) Percent reduction of FADD (black) or YY1 (red) oﬀ-target mRNA by PIK3CB siRNA in
control (solid lines) and Ago2-reduced (dashed lines) cells. (D) Percent reduction of oﬀ-target mRNA by PIK3CB RNAseH ASO in control and
Ago2-reduced cells.
Nucleic Acids Research, 2009,Vol.37, No. 20 6931Cleavage-deﬁcient siRNAs are able to promote
oﬀ-target and a fraction of target-speciﬁc
siRNA degradation
It has previously been demonstrated that substitution of
unmodiﬁed ribonucleotides with 20MOE modiﬁcations at
positions 1–3 or 12–14 of the siRNA guide strand results
in a reduction in target speciﬁc siRNA activity (34). We
synthesized PIK3CB siRNAs with three 20MOE modiﬁed
nucleotides at either the 50-end (PIK3CB-M1-3) or near
the center (PIK3CB-M12-14) of the guide strand in an
attempt to understand the role of Ago2 binding verses
cleavage on both target-speciﬁc and oﬀ-target siRNA
activity. As it has been shown that the Ago2 PIWI
domain is involved in 50-end recognition of the siRNA
guide strand (10,40), we expected that the increased size
of the 20MOE modiﬁcation relative to unmodiﬁed RNA
would aﬀect binding when placed at positions 1–3, but not
12–14. Binding aﬃnities of each guide strand for
recombinant Ago2 were determined by homologous satu-
ration using recombinant Ago2 as detailed in ‘Materials
and Methods’ section. While the unmodiﬁed guide
strand and the guide strand with MOE substitutions at
positions 12–14 were found to have similar aﬃnity
for Ago2, the binding aﬃnity of the guide strand with
MOE substitutions at positions 1–3 was  4-fold lower
(Figure 4A).
In vitro RNA cleavage was performed in the presence
of recombinant Ago2 using 40 nucleotide, P
32-labeled
RNA substrates corresponding to the region containing
the target site for the PIK3CB or YY1 siRNAs. No
cleavage of the YY1 oﬀ-target RNA was observed with
either the unmodiﬁed or the MOE substituted siRNAs
(Figure 4B, lanes 13–21). The unmodiﬁed siRNA
generated the expected PIK3CB cleavage product at
position 20 of the 40-mer target RNA, 10nt from the 50-
end of the antisense-strand (lanes 7–8). In total,  15%
substrate cleavage was observed. For PIK3CB-M12-14
only 0.25% cleavage of the targeted RNA was observed
(lanes 9–10), while incubation with PIK3CB-M1-3 siRNA
resulted in no detectable cleavage of the targeted RNA.
Next, HeLa cells were treated with PIK3CB, PIK3CB-
M1-3 or PIK3CB-M12-14 siRNAs at concentrations
ranging from 300pM to 300nM. The following day levels
of PIK3CB target-speciﬁc and YY1 oﬀ-target mRNA
reduction were evaluated by qRT–PCR. While the
10–9 10–8 10 –7 10 –6
–25
0
25
50
75
100 cont
-Ago2
-DCR
[siPIK3CB–20] M
%
 
r
e
d
u
c
t
i
o
n
 
P
I
K
3
C
B
 
m
R
N
A
A
10 –9 10 –8 10 –7 10 –6
–10
0
10
20
30
40
50
60
70 cont
-Ago2
-DCR
[siPIK3CB–20] M
%
 
r
e
d
u
c
t
i
o
n
 
Y
Y
1
 
m
R
N
A
B
10 –9 10 –8 10 –7 10 –6
–25
0
25
50
75
100
cont
-Ago2
-DCR
[siPIK3CB–40] M
%
 
i
r
e
d
u
c
t
i
o
n
 
P
I
K
3
C
B
 
m
R
N
A
C
10 –9 10 –8 10 –7 10 –6
–10
0
10
20
30
40
50
60
70 cont
-Ago2
-DCR
[siPIK3CB–40] M
%
 
r
e
d
u
c
t
i
o
n
 
Y
Y
1
 
m
R
N
A D
PIK3CB
YY1
Figure 2. Oﬀ-target activity requires ‘dicing’, but not Ago2 cleavage. The eﬀect of Dicer reduction on the potency of the 20-mer PIK3CB siRNA was
compared with a 40-mer RNA duplex targeting the same site. HeLa cells were treated with 50nM ASO targeting either Ago2 or Dicer. Twenty-four
hours later, the cells were seeded in 96-well plates and transfected with PIK3CB siRNA at concentration ranging from 330pM to 300nM. The
following day on-target and oﬀ-target IC50’s for PIK3CB siRNA were assessed for the 19- or 40-mer PIK3CB siRNAs by qRT–PCR. (A)I C 50 curves
for the reduction of PIK3CB with 20-mer siRNA in control (black), Ago2-reduced (blue) and Dicer-reduced (red) HeLa cells. (B)I C 50 curves for the
reduction of YY1 oﬀ-target mRNA in cells treated with 20-mer PIK3CB siRNA. (C) 40-mer siRNA on-target PIK3CB reduction. (D) Oﬀ-target
reduction of YY1 mRNA by PIK3CB 40-mer siRNA.
6932 Nucleic Acids Research, 2009,Vol.37, No. 20unmodiﬁed siRNA (black lines) eﬃciently reduced
PIK3CB messenger RNA, the siRNA with 20MOE
substitutions at position 12–14 (blue lines) was less potent
with a maximum target reduction of only 30% at the
highest concentration tested, as compared to  80% for
the unmodiﬁed siRNA (Figure 4C). The siRNA with
20MOE substitutions at position 1–3 (red lines) was
even less active, but did reduce PIK3CB mRNA by
 20% at the highest concentration. As previously
observed, the unmodiﬁed siRNA also reduced YY1
mRNA (Figure 4D), although the potency and activity at
the highest concentration tested were reduced compared to
PIK3CB on-target mRNA reduction. Reduction of the
YY1 oﬀ-target message by the PIK3CB-M12-14 siRNA
was equivalent to the unmodiﬁed siRNA, while no oﬀ-
target activity was observed for the PIK3CB-M1-3
siRNA. Similar results were obtained by analyzing oﬀ-
target reduction of FADD mRNA (data not shown). As
the PIK3CB-M12-14 siRNA supports only very limited
Ago2 mediated cleavage, these data again suggest that
Ago2 cleavage is not required for siRNA oﬀ-target
activity and that a fraction of on-target activity is Ago2
independent. However, Ago2 binding or binding to a
similar protein does appear to be required for both
target-speciﬁc and oﬀ-target activity, as no meaningful
activity was observed with the PIK3CB-M1-3 siRNA,
which does not promote target cleavage and binds to
Ago2 only very weakly. It should also be noted that in
our system, commercially available, chemically modiﬁed
siRNAs of the same sequence did not reduce oﬀ-target
eﬀects in a speciﬁc manner (Supplementary Figure S2).
Oﬀ-target and some on-target siRNA activity are
maintained in Ago2
–/– knockout cells
To address the possibility that the observed activities
could be accounted for by the fraction of Ago2 protein
remaining in HeLa cells following siRNA or RNaseH
ASO mediated Ago2 reduction, we evaluated both on-
and oﬀ-target siRNA activity in mouse embryonic
ﬁbroblasts (MEFs) derived from Ago2 knockout
(Ago2
–/–) mice (41). While the mouse and human YY1
oﬀ-target sites are perfectly complementary, the mouse
PIK3CB on-target site contains two base mismatches
relative to the human sequence. We therefore synthesized
a PIK3CB siRNA fully complementary to the homolo-
gous mouse PIK3CB target site. Both wild-type and
Ago2
–/– MEF cells were treated with mPIK3CB siRNA
at concentrations ranging from 300pM to 300nM. The
following day PIK3CB and YY1 mRNA reduction were
PIK3CB: 5’-UCUCCUAAUAUGAAUCCUAU-3’
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Figure 3. Ago2-dependent cleavage product is not detected for oﬀ-target siRNA. A modiﬁed RLM-RACE protocol was used to determine if oﬀ-
target mRNA degradation was Ago2 slicer/cleavage independent. HeLa cells were transfected with 30nM of either PIK3CB siRNA or an siRNA
designed with perfect complementarity to the YY1 oﬀ-target site. Eighteen hours later total RNA was isolated. (A) Percent reduction of PIK3CB or
YY1 mRNA was evaluated by qRT–PCR with gene speciﬁc primers. Solid bars, percent untreated control PIK3CB mRNA; Striped bars, percent
untreated control YY1 mRNA. The sequences of the PIK3CB on-target and the YY1 oﬀ-target mRNA transcripts are shown. Bold text indicates
mismatched nucleotides. Nucleotides complementary to the PIK3CB siRNA seed region are underlined and the siRNA cleavage site is indicated by
an arrow. (B) One microgram of total RNA was ligated to an RNA oligo. The ligated products were reverse transcribed, then subject to nested PCR
using primers speciﬁc for either PIK3CB or YY1. PCR products were visualized by electrophoresis on a 2% agarose gel and ethidium bromide
staining. The expected size of the PIK3CB (288) and YY1 (339) PCR products are shown.
Nucleic Acids Research, 2009,Vol.37, No. 20 6933evaluated by qRT–PCR (Figure 5). In wild-type cells
(black lines) the eﬃcacies of target-speciﬁc reduction of
PIK3CB (solid lines) and oﬀ-target reduction of YY1
(dotted lines) were similar to that previously observed in
HeLa cells. In the Ago2
–/– knockout cells (red lines), the
level of oﬀ-target reduction was nearly identical to that
observed in the wild-type cells and very similar to that
observed in the human cell line (Figure 4D), conﬁrming
that oﬀ-target mRNA degradation can occur even in the
absence of Ago2. In contrast, PIK3CB was reduced less
eﬃciently in the knockout as compared to the wild-type
cells. The extent of on-target reduction in the knockout
cells was very similar to that observed for oﬀ-target
reduction, suggesting that fully complementary on-target
siRNAs are able to promote mRNA reduction even in the
absence of Ago2, albeit less eﬃciently than in wild-type
cells.
One possible explanation for the oﬀ-target activity in
Ago2
–/– MEFs is that another Ago may be able to be
used mechanistically to duplicate the function of Ago2
in oﬀ-target activity. All four Ago proteins have been
shown to be associated with small RNAs in mammalian
cells (42). Although only Ago2 has been determined to
have slicer activity (41), previous studies have shown
Dcr1 and Ago1 to be essential for the miRNA pathway
(8,43). Alternatively, Supplementary Figure S3 suggests
A
B
D C
siRNA SEQUENCE AGO2 KD(nM)
control AUAGGAUUCAUAUUAGGAGU  324±77
MOE 1-3 AUAGGAUUCAUAUUAGGAGU 1059±56
MOE 12-14 AUAGGAUUCAUAUUAGGAGU 234±94
G(22)
G(35)
1  2  3  4    5   6    7  8   9  10  11 12    13 14 15 16  17 18 19  20  21
none
YY1 PIK3CB
cont 12-14 1-3 T1 OH cont 12-14 1-3 none OH
10 –9 10 –8 10 –7 10 –6
–10
0
10
20
30
40
50 control
MOE 1-3
MOE 12-14
[siRNA] M
%
 
r
e
d
u
c
t
i
o
n
 
Y
Y
1
 
m
R
N
A
10 –9 10 –8 10 –7 10 –6
–10
0
10
20
30
40
50
60
70
80
90 control
MOE 1-3
MOE 12-14
[siRNA] M
%
 
r
e
d
u
c
t
i
o
n
 
P
I
K
3
C
B
 
m
R
N
A
Figure 4. MOE modiﬁcation at positions 12–14 of the siRNA attenuates some target-speciﬁc, but not oﬀ-target activity. PIK3CB siRNAs were
synthesized with 20MOE modiﬁed nucleotides at positions 1–3 (MOE 1–3) or 12–14 (MOE 12–14) of the guide strand. (A) In vitro binding aﬃnity for
recombinant Ago2 was determined as detailed in ‘Materials and Methods’ section. (B) An Ago2 based in vitro RNA cleavage assay was utilized to
evaluate cleavage of the targeted mRNA by the parent and MOE-substituted PIK3CB siRNAs. RNA cleavage was performed using a 40 nucleotide
32P-labeled RNA substrate corresponding to the region containing the PIK3CB on-target or YY1 oﬀ-target site for the PIK3CB siRNA. (C) HeLa
cells were treated with unmodiﬁed or MOE-substituted PIK3CB siRNAs at concentrations ranging from 300pM to 300nM. The following day
target-speciﬁc PIK3CB (C) and oﬀ-target YY1 (D) mRNA reduction was evaluated by qRT–PCR. Control PIK3CB siRNA (black), PIK3CB-M1-3
siRNA (red), PIK3CB-M12-14 siRNA (blue).
6934 Nucleic Acids Research, 2009,Vol.37, No. 20that in the presence of adequate levels of Ago2, reduction
of any one of the other Agos has little eﬀect. Therefore, we
evaluated the eﬀect of Ago1 reduction on siRNA on- and
oﬀ-target activity in MEF Ago2
–/– cells. Ago2
–/– MEF
cells were treated for 48h with an RNaseH-dependent
ASO targeting Ago1, followed by treatment with
mPIK3CB siRNA as detailed above. Ago1 reduction
was conﬁrmed by both qRT–PCR and western blot
(Supplementary Figure S4) and resulted in a decrease in
both on-target reduction of PIK3CB and oﬀ-target reduc-
tion of YY1 mRNA treated with the mPIK3CB siRNA
(Figure 5, blue lines). These data suggest that either Ago1
or Ago2 can bind an siRNA and mediate oﬀ-target
mRNA reduction. In addition, a signiﬁcant proportion
of on-target mRNA reduction appears to use an Ago2
slicer-independent mechanism and is apparently indepen-
dent of Ago2. We also evaluated the eﬀect of reducing
Ago3 on activity in Ago2
–/– MEF cells as well
(Supplementary Figure S5). However, while reduction of
Ago3 did attenuate oﬀ-target mRNA reduction, the eﬀect
was not as signiﬁcant as that observed with Ago1 reduc-
tion. We were unable to evaluate the eﬀect of Ago4 reduc-
tion, however, as the levels of Ago4 mRNA were more
than 20-fold less than those of Ago1 and Ago3.
The oﬀ-target activity of PIK3CB-M1-3 or PIK3CB-
M12-14 siRNAs was also compared in MEF Ago2
–/–
cells (Figure 6). While these siRNAs were designed to
the human PIK3CB sequence, they are capable of
promoting oﬀ-target reduction of mouse YY1 which is
perfectly complementary to the human sequence at the
YY1 oﬀ-target site. MEF Ago2
–/– cells treated at
100nM with siRNA PIK3CB-M12-14 (striped bars) or
the unmodiﬁed PIK3CB siRNA (solid bars) showed
similar levels of activity in reducing the YY1 oﬀ-target
message, while siRNA PIK3CB-M1-3 (hatched bars)
was signiﬁcantly less active. Pre-treatment with an
RNAseH ASO targeting Ago1 reduced YY1 oﬀ-target
activity of PIK3CB and PIK3CB-M12-14 siRNAs to
approximately equal levels, as observed for siRNA
PIK3CB-M1-3 in the untreated cells, conﬁrming that the
MOE substituted siRNA is also capable of mediating oﬀ-
target reduction via either Ago1 or Ago2.
Aﬀymetrix expression analysis of oﬀ-target eﬀects
in wild-type and Ago2
–/– MEF cells
To further conﬁrm that siRNA mediated oﬀ-target
mRNA reduction can occur in the absence of Ago2 and
to expand our observations beyond a single oﬀ-target
transcript, gene expression analysis was performed in
siRNA treated MEF cells. Wild-type and Ago2
–/–
knockout cells were treated with PIK3CB siRNA at
10nM. The following day RNA was puriﬁed and
Aﬀymetrix Mouse Genome 430 2.0 arrays used to deter-
mine mRNA proﬁles and identify genes whose expression
levels were changed in siRNA-treated, compared to mock
transfected cells as detailed in ‘Materials and Methods’
section.
In the wild-type MEF cells treated with PIK3CB
siRNA, a hexamer (ATCCTA), corresponding to
nucleotides 2–7 of the siRNA guide strand was strongly
over-represented in the population of down-regulated
transcripts (Figure 7A). The results were similar in MEF
Ago2
–/– cells, where again transcripts containing the ATC
CTA hexamer were signiﬁcantly over-represented in the
population of down-regulated transcripts (Figure 7B). In
addition, transcripts containing the hexamer AATCCT,
complementary to position 3–8 of the siRNA, were also
reduced (not shown). Further, PIK3CB was down-
regulated  44% (average of ﬁve probes). Since on- and
oﬀ-target silencing follow similar dose-response curves, it
is likely that oﬀ-target silencing was also suboptimal in
this experiment.
P-body associated proteins are involved in oﬀ-target
degradation of messenger RNA
Our data suggested that oﬀ-target siRNA activity and a
fraction of on-target activity require the presence of Ago1
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Figure 5. PIK3CB oﬀ-target and some on-target activity is maintained
in mouse Ago2
–/– cells. MEF cells were treated with mPIK3CB siRNA
at concentrations ranging from 300pM to 300nM as detailed in
‘Materials and Methods’ section. The following day total RNA was
isolated. Percent reduction of mPIK3CB (solid lines) or YY1 (dashed
lines) mRNA was evaluated by qRT–PCR with gene speciﬁc primers in
wild-type (black), Ago2
–/– (red), or Ago2
–/– MEF cells treated 24h
prior to the siRNA transfections with an RNAseH ASO to reduce
Ago1 (blue). The level of Ago1 reduction was evaluated by qRT–
PCR and western blot and found to be <75% control following treat-
ment with the RNAseH ASO (Supplementary Figure S4).
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Figure 6. Activity of MOE modiﬁed siRNAs in mouse Ago2
–/– cells.
Ago2
–/– MEF or Ago2
–/– MEF pre-treated for 24h an RNAseH ASO
to reduce Ago1 were transfected with PIK3CB (solid bars), PIK3CB-
M1-3 (crosshatched) or PIK3CB-M12-14 (striped) siRNAs at 100nM.
Percent reduction of mouse YY1 mRNA as evaluated by qRT–PCR is
shown (asterisk, conﬁdence level  95%).
Nucleic Acids Research, 2009,Vol.37, No. 20 6935and/or Ago2; yet do not require Ago2 cleavage. Given the
importance of 50 seed region homology for both oﬀ-target
mRNA down-regulation and miRNA mediated RNA
degradation, it seems likely that both of these eﬀects
share common mechanisms. It has been demonstrated
that miRNAs promote mRNA degradation by directing
deadenylation then subsequent decapping and
exonucleolytic degradation of messages to which they
are partially complementary (21). Several groups have
shown that both Ago1 and Ago2 proteins localize to
mammalian P-bodies where they associate with other
P-body components known to be involved in mRNA
turnover (44–46). One suggested model for the mechanism
by which miRNAs promote mRNA degradation is that
miRNAs may bind to either Ago1 or Ago2 in a
common complex. Ago1 and Ago2, along with associated
proteins, then release the message from a translation
pathway and allow P-bodies to form where the mRNA
is subsequently subject to decapping and exonucleolytic
degradation (47). By this mechanism, degradation of the
message may occur even in the absence of Ago2-mediated
cleavage. We reasoned that the binding and subsequent P-
body sequestration functions may in fact be redundant
between Ago1 and Ago2. We therefore performed
experiments to evaluate the eﬀect of reducing P-body
associated proteins on oﬀ-target activity.
Ago2
–/– MEF cells were treated with an RNaseH-
dependent ASOs targeting Ago1 or GW182, a P-body
component whose depletion has previously been
demonstrated to impair gene silencing by miRNAs (27).
After 72h, the cells were treated with PIK3CB siRNA at
concentrations ranging from 300pM to 300nM.
Reduction of Ago1 and GW182 mRNA was evaluated
by qRT–PCR and found to be >85% for both proteins
(Figure 8A). YY1 oﬀ-target mRNA expression was
assessed the following day. Signiﬁcant YY1 oﬀ-target
mRNA reduction was observed in the mock treated
Ago2
–/– MEF cells with  60% oﬀ-target reduction at
the 100nM concentration (Figure 8B, blue line). In
contrast, in the Ago1 or GW182 depleted Ago2
–/– MEF
cells, levels of YY1 mRNA reduction were signiﬁcantly
less; in both cases less than  15% reduction in YY1
message was observed at a concentration of 100nM.
DCP1 and DCP2 are P-body associated proteins which
have previously been reported to play a role in miRNA-
mediated gene silencing (25). Ago2
–/– MEF cells were
treated with ASOs targeting GW182 at 100nM or DCP1
and DCP2 at 50nM each. Three days later the cells were
treated with 100nM PIK3CB siRNA and levels of YY1
oﬀ-target mRNA subsequently assessed by qRT–PCR.
Reduction of DCP1:2 and GW182 mRNA was assayed
by qRT–PCR and found to be >70% and the ability of
the ASOs to disrupt P-body formation was also conﬁrmed
by immunoﬂuorescence (Supplementary Figure S6).
Depletion of both DCP1:2 and GW182 resulted in a >2-
fold reduction in oﬀ-target activity (Figure 8C). In
contrast, DCP1:2 and GW182 depletion had no signiﬁcant
eﬀect on target-speciﬁc, Ago2-independent mRNA reduc-
tion, as there was no signiﬁcant diﬀerence in the amount
of PIK3CB siRNA reduction in the same cells (Figure
8D). Depletion of DDX6, which has been demonstrated
to be contained within P-bodies and has previously been
reported to play a role in miRNA-mediated gene silencing
(46), was also found to attenuate oﬀ-target activity in
Ago2
–/– MEF cells (Supplementary Figure S7).
The eﬀect of reduction of P-body associated proteins on
target-speciﬁc as well as oﬀ-target activity was evaluated
in HeLa cells as well. Cells were treated with siRNAs
targeted to P-body components LSM-1 or GW182. An
siRNA targeting Ago2 was also included as a control.
Twenty-four hours later cells were seeded in 96-well
plates, then treated with PIK3CB siRNA at
concentrations ranging from 10pM to 40nM. ASO-
mediated mRNA reduction of the targeted P-body
proteins and subsequent disruption of P-body formation
was conﬁrmed by immunoﬂuorescence (Supplementary
Figure S8). Levels of PIK3CB and YY1 mRNA were
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Figure 7. Oﬀ-target transcripts matching PIK3CB siRNA seed hexamer
are down-regulated in MEF wild type and Ago2
 /  knockout cells.
Wild-type and Ago2
 /  MEF cells were treated with 10nM PIK3CB
siRNA. The following day, RNA was puriﬁed and subjected to
microarray analysis. 30UTR regions associated with probes from each
bin were analyzed for increased or reduced expression of all 4096
possible hexamer words. Shown are the maximum rank and enrichment
in downregulation ( log10 hypergeometric P-value) for each possible
hexamer motif in expression signatures from wild type (top) and
Ago2
–/– knockout (bottom) MEFs. PIK3CB seed: the hexamer
matching residues 2–7 of the PIK3CA siRNA seed region (ATCCTA);
other hexamers: hexamers other than ATCCTA.
6936 Nucleic Acids Research, 2009,Vol.37, No. 20assessed by qRT–PCR the following day. As previously
observed, reduction of Ago2 (blue lines) resulted in a
6-fold reduction in on-target siRNA activity (Figure 8E),
but had no eﬀect on oﬀ-target potency as measured by the
reduction of YY1 mRNA (Figure 8F). Conversely, reduc-
tion of the P-body proteins (red and green lines) had
no eﬀect on PIK3CB on-target mRNA reduction, but
did reduce oﬀ-target potency by  3-fold suggesting that
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Figure 8. P-body associated protein reduction attenuates siRNA oﬀ-target activity. (A) Reduction of total RNA after 72h ASO treatment. Relative
expression levels of Ago1 (solid bars) and GW182 (striped bars) were measured by qRT–PCR. (B) Ago2
 /  MEF cells were treated with RNAseH
ASOs targeting Ago1 or GW182. Seventy-two hours later cells were treated with PIK3CB siRNA at concentrations ranging from 300pM to 300nM
levels of YY1 mRNA were assessed by qRT–PCR the following day. (C) Ago2
 /  MEF cells were treated with RNAseH ASOs targeting GW182 or
DCP1:2. Seventy-two hours later cells were treated with PIK3CB siRNA at 100nM. Levels of YY1 mRNA reduction were assessed as above. (D)A s
in (B), but levels of PIK3CB reduction were measured. (E)I C 50 curves for PIK3CB on-target mRNA reduction. HeLa cells were treated with
siRNAs targeted to P-body components LSM-1 or GW182 as above. An siRNA targeting Ago2 was also included as a control. Twenty-two hours
later cells were seeded in 96-well plates, then treated with PIK3CB siRNA at concentrations ranging from 10pM to 40nM. Levels of PIK3CB
mRNA were assessed by qRT–PCR the following day for control (black), Ago2 reduced (blue), GW182 reduced (red), or LSM1 reduced
(green) cells. (F)I C 50 curves for YY1 oﬀ-target mRNA reduction. Levels of YY1 mRNA were assessed by qRT–PCR using RNA isolated from
HeLa cells above.
Nucleic Acids Research, 2009,Vol.37, No. 20 6937oﬀ-target RNA degradation is dependent on some
of the same P-body associated protein previously demon-
strated to be involved in miRNA mediated RNA
degradation.
DISCUSSION
In this article, we have demonstrated that siRNA-
mediated reduction of an oﬀ-target messenger RNA is
Ago2 cleavage independent, but does require siRNA inter-
action with either Ago1 or Ago2 and the RLC. We also
show that oﬀ-target siRNA-mediated degradation of
mRNA is associated with proteins that have previously
been shown to localize to P-bodies. Finally, our data
suggest that a portion of on-target siRNA mediated
mRNA degradation is also Ago2 cleavage independent,
but may use mechanism diﬀerent than that used for oﬀ-
target mRNA degradation.
Experiments in both human and mouse cells
demonstrated that siRNAs can reduce target-speciﬁc and
oﬀ-target mRNAs via a mechanism that is independent of
Ago2 slicer activity. It has previously been reported that
siRNA mediated oﬀ-target mRNA reduction of a stably
expressed reporter gene is likely the result of Ago-2 inde-
pendent degradation processes (28). Another recently pub-
lished article reported that translational repression
mediated by siRNAs with full complementarity to a
reporter mRNA can also occur independently of Ago2
(29). We extended these observations, demonstrating in
HeLa cells that RNAseH ASO mediated reduction of
Ago2 has no eﬀect on siRNA oﬀ-target degradation of
endogenous mRNAs (Figure 1C). Moreover, reduction
of Ago2 decreased the maximum reduction of the target,
PIK3CB, from 70 to 50% and resulted in a 6-fold shift
in the IC50 but did not completely ablate the activity
(Figure 1A). We conﬁrmed and extended this observation
by demonstrating that Dicer activity is required for both
on- and oﬀ-target activities if Dicer substrates are used
(Figure 2). This suggests that although Ago2 is not
responsible for all of the on-target activities and very
little if any of the oﬀ-target activities of the siRNAs
used in this study, the RLC is likely involved in all the
activities. Less of an eﬀect of Ago2 reduction on PIK3CB
silencing was observed at higher siRNA concentrations.
This may also suggest that at higher siRNA concentra-
tions activity may be mediated by an Ago2-independent
mechanism.
It is known that cleavage of a target by Ago2 leaves a 50
phosphate on the cleaved mRNA. To further conﬁrm that
Ago2 cleavage is not required for oﬀ target siRNA
activities, we attempted to detect the cleavage fragments
expected for Ago2 cleavage utilizing a modiﬁed RLM-
RACE technique. As expected, for on-target activity the
Ago2 cleavage product was detected. However, we were
unable to detect any Ago2 speciﬁc fragments correspond-
ing to the oﬀ-target mRNA reductions (Figure 3B). It
could be argued that we simply did not detect a RACE
product due to the lower eﬃcacy of oﬀ-target as compared
to target-speciﬁc activity; however, we were able to detect
a RACE product for the YY1 siRNA which had much
lower activity than either the target-speciﬁc or oﬀ-target
activity of the PIK3CB siRNA (Figure 3A). A second site
with homology to the PIK3CB siRNA seed region was
found in the YY1 mRNA; however, we were unable to
design PCR primers for this site since it ends a single
nucleotide from the 30 end of the message. If cleavage
occurs via siRNA interactions with this site, it would
not be detected with the primers used. However, our
results suggest that if degradation of oﬀ-target transcripts
occurs via siRNA interactions at the putative cleavage site
for which the RACE primers were designed, it occurs via
an Ago2 slicer-independent mechanism.
Studies with siRNAs modiﬁed in key positions with
20-MOE nucleotides provided additional conﬁrmation
and suggested that binding to a member of the Ago
family may be required for oﬀ-target activity. It has
previously been shown that 20-O-methyl ribosyl substitu-
tion of the siRNA guide strand at position 2 reduces oﬀ-
target activity but has little to no eﬀect on target-speciﬁc
mRNA reduction (48), indicating that on- and oﬀ-target
mechanisms may be diﬀerentially sensitive to chemical
modiﬁcations of the siRNA. Modiﬁed siRNAs substituted
with 20-MOE nucleotides at various positions have been
shown to result in reduction of siRNA activity (34),
however, the eﬀect of these modiﬁcations on oﬀ-target
activity has not been evaluated. PIK3CB siRNAs with
three 20MOE modiﬁed bases at either the 50-end or near
the center of the guide strand were synthesized, then
evaluated for Ago2 binding and cleavage as well as on-
and oﬀ-target activities. Based upon the crystal structure
of an siRNA guide strand with the Ago2 PIWI domain
(10,40), we predicted that the increased size of the 20MOE
modiﬁcation at positions 1–3 of the siRNA guide strand
relative to unmodiﬁed or 20-O-methyl RNA would inter-
fere with binding to Ago2. As expected, inserting 20-MOEs
in positions 1–3 of the guide strand reduced aﬃnity
for Ago2 by 3-fold and consequently, ablated cleavage
activity (Figure 4A and B). Even so, the siRNA
modiﬁed at positions 1–3 displayed some siRNA
activity, albeit very substantially less than the parent.
However, oﬀ-target activity was essentially ablated in
cells treated with PIK3CB-M1-3 siRNA. In contrast to
PIK3CB-M1-3 siRNA, the siRNA with 20-MOE
substitutions at positions 12–14 had essentially the same
binding aﬃnity for recombinant Ago2 as the unmodiﬁed
siRNA (Figure 4A), but a nearly 60-fold reduction in
cleavage activity (Figure 4B). This was associated with a
2log drop in potency for on-target activity and a signiﬁ-
cant reduction in the maximum eﬀect (Figure 4C). In
contrast to PIK3CB-M1-3 siRNA, PIK3CB-M12-14
siRNA resulted in the same amount of oﬀ-target activity
as the unmodiﬁed siRNA, conﬁrming that oﬀ-target
activity is independent of Ago2 cleavage activity, but sug-
gesting a requirement for binding to Ago2 or a similar
protein.
Because siRNAs/ASOs reduced Ago2 levels in Hela
cells by 80–90%, but did not eliminate all Ago2, it is
possible that the activities observed could be mediated
by the residual Ago2 activity that remained in ASO or
siRNA treated cells. To evaluate this possibility and to
begin to try to understand the mechanisms by which
6938 Nucleic Acids Research, 2009,Vol.37, No. 20these eﬀects are mediated, we studied on- and oﬀ-target
mRNA degradation in Ago2
–/– knockout MEF cells (41).
Again, on-target activity was less potent in the knockout
as compared to the wild-type cells, but still substantial for
the siRNA studied and oﬀ-target activity was virtually
identical in the wild type and knockout cells (Figures 5).
These observations were conﬁrmed by the behaviors of the
20-MOE modiﬁed siRNAs in the knockout cells (Figure 6).
Furthermore, to exclude the possibility that oﬀ-target
activities for mRNAs other than YY1 are mediated by a
mechanism diﬀerent from the process suggested by our
data, we performed a gene expression array analysis for
all potential oﬀ-target eﬀects. In both wild-type and
Ago2
–/– MEF cells treatment with PIK3CB siRNA
resulted in the reduction of a set of transcripts containing
the ATCCTA hexamer which is complementary to the
PIK3CB siRNA seed region hexamer (Figure 7).
While slicer activity, which contributes to a substantial
proportion of target-speciﬁc siRNA mediated cleavage, is
associated with Ago2 only (9), the high degree of similar-
ity of the other Ago proteins suggests a substantial degree
of redundancy in the Ago protein family (49). Analysis of
Ago1 and Ago2 containing protein complexes suggests
that both Ago1 and Ago2 proteins may be components
of miRNA-containing mRNA targeting complexes (50).
Given the similarity between oﬀ-target silencing by
siRNAs and transcript regulation by miRNAs, we
explored the possibility that Ago1 might be capable of
mediating oﬀ-target activity. Reduction of Ago1 with an
RNaseH dependent ASO resulted in a further reduction of
oﬀ-target as well as target-speciﬁc activity in Ago2
–/–
MEF cells with both unmodiﬁed and 20-MOE modiﬁed
siRNAs (Figures 5, 6 and 8). These results suggest that
some on-target mRNA degradation may be, in part,
mediated by Ago1 and that Ago1 can play a signiﬁcant
role in oﬀ-target degradation activities, and are consistent
with a recently published paper describing overlapping
functions for all four mammalian Ago proteins in
miRNA silencing (51). We also observed attenuation of
oﬀ-target activity resulting from reduction of Ago3
(Supplementary Figure S5), however, levels of Ago4
expression were too low in the Ago2
–/– MEF cells to
conclusively observe an eﬀect on activity.
Several studies that have demonstrated that miRNA
can induce degradation of mRNA targets despite imper-
fect miRNA-mRNA base-pairing (19,20,25,52). Like our
observations for oﬀ-target activity, this miRNA-mediated
mRNA degradation is Ago-dependent, however, it does
not require the direct Ago2-mediated endonucleolytic
cleavage of the target mRNA. Target degradation is
instead a consequence of decapping and exonucleolytic
processing of repressed mRNAs (53). To further under-
stand the mechanism supporting Ago2 independent eﬀects
of siRNAs, we reduced the levels of several P-body
associated proteins (54) in Ago2
–/– MEF cells and in
Hela cells. In Ago2
–/– MEF cells, reduction of DDX6,
GW182 and DCP1:2 caused a loss of oﬀ-target activity
comparable to that achieved with Ago1 reduction
(Figures 8B and C, Supplementary Figures S6 and S7).
In Hela cells, we showed that reduction of P-body
associated proteins, LSM1 and GW182 also reduced
oﬀ-target activity (Figure 8F). These data suggest that
oﬀ-target mRNA degradation is P-body associated.
However, this correlation does not prove that P-bodies
are the site of oﬀ-target degradation, as P-body formation
and oﬀ-target degradation may simply require some of the
same proteins. In addition, one would expect that P-body
reduction would also reduce the fraction of Ago2-
independent on-target activity. It is interesting to note,
however, that P-body reduction in wild-type MEF and
HeLa cells had no eﬀect on target-speciﬁc activity
(Figure 8D and E). While Ago2 independent on-target
RNA degradation clearly involves the RLC and an Ago
protein, it may not be aﬀected via P-body associated
proteins. Alternatively, any eﬀects of P-body reduction
on Ago2 independent on-target activity may be masked
by the more robust slicer-dependent activity in these cells
or degradation may be occurring in some other cellular
compartment such as the exosome (55).
In conclusion, we have demonstrated that siRNA
induced oﬀ-target activities do not require Ago2 slicer
activity, but do require interaction with Ago1 and
P-body associated proteins. Moreover, a fraction of
siRNA mediated on-target activity is independent of
Ago2, dependent on Ago1, and unaﬀected by reduction
of the P-body proteins that we studied. Nevertheless, both
on- and oﬀ-target activities are mediated by the RLC.
These results are consistent with the previously published
observation that RISC assembly can occur in the absence
of passenger strand cleavage (5). Our results are also
consistent with observations that the puriﬁed enzyme
can only engage in a single round of cleavage (11).
Given the inability of Ago2 to release product and the
absence of cleavage by the other Ago proteins, one is
forced to wonder if the slicer activity of Ago2 accounts
for only a portion of observed activities, and, like the
other Ago proteins, Ago2 activity may also be the result
of binding to and transport of targeted RNAs to sites of
degradation employing other enzymatic processes.
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